The MASTER study (NCT03224507) and GRIFFIN study (NCT02874742) evaluated the efficacy of daratumumab-containing regimens in transplant-eligible newly diagnosed patients with multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCAs).

Read More> https://multiplemyeloma.pocn.com/treatment/efficacy-of-daratumumab-regimens-in-transplant-eligible-patients-with-ndmm-with-high-risk-cytogenetic-abnormalities/